These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 16917408)

  • 1. Nonalcoholic fatty liver disease presenting with an isolated elevated alkaline phosphatase.
    Pantsari MW; Harrison SA
    J Clin Gastroenterol; 2006 Aug; 40(7):633-5. PubMed ID: 16917408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up of patients with NAFLD and elevated liver enzymes.
    Ekstedt M; Franzén LE; Mathiesen UL; Thorelius L; Holmqvist M; Bodemar G; Kechagias S
    Hepatology; 2006 Oct; 44(4):865-73. PubMed ID: 17006923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.
    Williams CD; Stengel J; Asike MI; Torres DM; Shaw J; Contreras M; Landt CL; Harrison SA
    Gastroenterology; 2011 Jan; 140(1):124-31. PubMed ID: 20858492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonalcoholic fatty liver disease in patients investigated for elevated liver enzymes.
    Kichian K; McLean R; Gramlich LM; Bailey RJ; Bain VG
    Can J Gastroenterol; 2003 Jan; 17(1):38-42. PubMed ID: 12560853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Eslami L; Merat S; Malekzadeh R; Nasseri-Moghaddam S; Aramin H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008623. PubMed ID: 24374462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
    Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Liver enzymes elevation: etiologic study and efficiency of a single-act office visit].
    Bendezú García RÁ; Casado Martín M; Lázaro Sáez M; Patrón Román GÓ; Gálvez Miras A; Rodríguez Laiz GP; González Sánchez M; Vega Sáenz JL
    Gastroenterol Hepatol; 2013; 36(7):450-6. PubMed ID: 23850511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonalcoholic fatty liver disease: a potential consequence of tumor necrosis factor-inhibitor therapy.
    Feagins LA; Flores A; Arriens C; Park C; Crook T; Reimold A; Brown G
    Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1154-60. PubMed ID: 26148245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease.
    Hossain N; Afendy A; Stepanova M; Nader F; Srishord M; Rafiq N; Goodman Z; Younossi Z
    Clin Gastroenterol Hepatol; 2009 Nov; 7(11):1224-9, 1229.e1-2. PubMed ID: 19559819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical, biochemical and histological differences between HIV-associated NAFLD and primary NAFLD: a case-control study.
    Vodkin I; Valasek MA; Bettencourt R; Cachay E; Loomba R
    Aliment Pharmacol Ther; 2015 Feb; 41(4):368-78. PubMed ID: 25496369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonalcoholic fatty liver disease treated by gastroplasty.
    Jaskiewicz K; Raczynska S; Rzepko R; Sledziński Z
    Dig Dis Sci; 2006 Jan; 51(1):21-6. PubMed ID: 16416204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
    Sato K; Gosho M; Yamamoto T; Kobayashi Y; Ishii N; Ohashi T; Nakade Y; Ito K; Fukuzawa Y; Yoneda M
    Nutrition; 2015; 31(7-8):923-30. PubMed ID: 26059365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular disease and nonalcoholic fatty liver disease: does histologic severity matter?
    Domanski JP; Park SJ; Harrison SA
    J Clin Gastroenterol; 2012; 46(5):427-30. PubMed ID: 22469639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver.
    Pais R; Charlotte F; Fedchuk L; Bedossa P; Lebray P; Poynard T; Ratziu V;
    J Hepatol; 2013 Sep; 59(3):550-6. PubMed ID: 23665288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease.
    Ozturk O; Colak Y; Senates E; Yilmaz Y; Ulasoglu C; Doganay L; Ozkanli S; Oltulu YM; Coskunpinar E; Tuncer I
    World J Gastroenterol; 2015 Jul; 21(26):8096-102. PubMed ID: 26185381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up of patients with nonalcoholic fatty liver.
    Rafiq N; Bai C; Fang Y; Srishord M; McCullough A; Gramlich T; Younossi ZM
    Clin Gastroenterol Hepatol; 2009 Feb; 7(2):234-8. PubMed ID: 19049831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values.
    Mofrad P; Contos MJ; Haque M; Sargeant C; Fisher RA; Luketic VA; Sterling RK; Shiffman ML; Stravitz RT; Sanyal AJ
    Hepatology; 2003 Jun; 37(6):1286-92. PubMed ID: 12774006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease.
    Palekar NA; Naus R; Larson SP; Ward J; Harrison SA
    Liver Int; 2006 Mar; 26(2):151-6. PubMed ID: 16448452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonalcoholic fatty liver disease: a systematic review.
    Rinella ME
    JAMA; 2015 Jun; 313(22):2263-73. PubMed ID: 26057287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Insulin-like growth factor-binding protein-1: a new biochemical marker of nonalcoholic fatty liver disease?].
    Graffigna MN; Belli SH; de Larrañaga G; Fainboim H; Estepo C; Peres S; García N; Levalle O
    Acta Gastroenterol Latinoam; 2009 Mar; 39(1):30-7. PubMed ID: 19408737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.